You might also like
Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of complex sterile injectable pharmaceutical products. The company manufactures premium, injectable-grade sodium hyaluronate (HA) used as an active pharmaceutical ingredient (API) in various medical applications. Lifecore operates across multiple facilities, providing pharmaceutical-grade products and services to global biopharmaceutical and biotechnology companies.
- Contract Development and Manufacturing Organization (CDMO) - Develops, fills, and finishes sterile injectable pharmaceutical products in syringes, vials, and cartridges, offering services such as formulation technology development, analytical method development, clinical production, and commercial production.
- Sodium Hyaluronate (HA) Manufacturing - Produces premium, injectable-grade HA using fermentation processes, supporting applications in wound care, aesthetic surgery, drug delivery, orthopedics, and device coatings.
- How do you expect potential shifts toward domestic drug manufacturing, as discussed at DCAT, to impact your cost structure and competitive positioning, especially given the current operational margins?
- With the Humanetics tech transfer contract being characterized as a Phase II project, can you clarify the specific regulatory and operational challenges you anticipate in transitioning this program?
- Considering your goal of a 12% revenue CAGR and over 25% EBITDA margins amid ongoing legacy legal expenses and adjustments in SG&A, what measures are in place to ensure these targets remain achievable?
- Given the noted decline in CDMO revenues and gross profit, what specific strategies will you employ to reverse this trend while capitalizing on the growth in HA manufacturing?
- In light of your Q3 cash flow being close to free cash flow breakeven, what contingency plans do you have if the remaining $10 million from the filler sale is delayed or if CapEx exceeds your guidance?
Recent press releases and 8-K filings for LFCR.
LifeCore Biomedical Approves Convertible Preferred Issuance Proposal
$LFCRProxy Vote Outcomes
Convertible Preferred Issuance
- On April 10, 2025, LifeCore Biomedical held a special stockholders meeting (with a record date of February 18, 2025) to address a proposal concerning the issuance of shares underlying Series A Convertible Preferred Stock, along with an adjournment proposal.
- The meeting resulted in the approval of the issuance proposal, with 24,098,218 votes for, 444,639 votes against, and 33,281 abstentions; the adjunct adjournment proposal was approved in principle but not executed due to the issuance proposal's success.
Apr 10, 2025, 12:00 AM